Italian Hospital conducts a Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi is commencing recruitment for the clinical trial of the Prospective Pilot Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 (ANG1) and Endothelial Internal Tunica Cell Kinase 2 (TiE2) in Patients With Ovarian Cancer Treated With Chemotherapy Associated to bevAcizumab.
The condition is Ovarian Cancer.
A new clinical trial is recruiting patients in the following locations: Italy.
The trial officially began on the October 12, 2020 and is planned to complete on March 2023.
This is a study of translational research in women with advanced ovarian epithelial cancer. The main purpose of this study is to evaluate the predictive value of response to treatment with bevacizumab of the circulating levels of Ang1, Tie2 and VEGF before start of therapy. Secondary aims of the study are to explore the predictive value of response / resistance to bevacizumab of changes in circulating levels of Ang1 and Tie2 during treatment and at progression of disease, and to explore the possible role of circulating VEGF in the modulation of bioavailability of bevacizumab.
Among the inclusion criteria are:
- Patients ≥ 18 years old
- Diagnosis of histologically confirmed advanced epithelial ovarian carcinoma
- Women eligible for treatment with a chemotherapy regimen in combination to bevacizumab (Cohort A)
- Women eligible for treatment with a chemotherapy regimen not associated to antiangiogenic drugs (Cohort B)
- Evaluable disease according to RECIST 1.1 criteria
Ospedale SS Giovanni e Paolo, Venezia is the collaborator in this clinical trial.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04770376
